Article
Y-box binding protein-1 is crucial in acquired drug resistance development in metastatic clear-cell renal cell carcinoma.
Journal of experimental & clinical cancer research : CR - 10 Feb 2020
D'Costa Ninadh M, Lowerison Matthew R, Raven Peter A, Tan Zheng, Roberts Morgan E, Shrestha Raunak, Urban Matthew W, Monjaras-Avila Cesar U, Oo Htoo Zarni, Hurtado-Coll Antonio, Chavez-Munoz Claudia, So Alan I
Abstract excerpt
BACKGROUND: Renal cell carcinoma (RCC) is a highly vascular tumor and patients with low risk metastatic RCC of clear-cell histological sub-type (mccRCC) are treated with tyrosine-kinase inhibitors (TKIs), sunitinib, as the first-line of treatment. Unfortunately, TKI resistance eventually develops, and the underlying molecular mechanism is not well understood. METHODS: RCC cell-line with metastatic clear-cell...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.